Physician profile
Thomas E Meek
NPI 1083713812
$769.46
in general payments reported to CMS, 2019-2025
11 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $61.17 · 2022: $26.24 · 2023: $62.63 · 2024: $241 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $682.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $682.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Indivior INC. | $370.58 | 2021-2025 | Sublocade |
| Gilead Sciences, INC. | $102.95 | 2023-2025 | |
| Alkermes, INC. | $56.63 | 2021-2025 | Vivitrol, Vivitrol |
| Exact Sciences Corporation | $48.34 | 2024-2025 | The Cologuard Plus Collection Kit, Cologuard Collection Kit |
| Lilly USA, LLC | $37.20 | 2025 | Mounjaro, Zepbound |
| Braeburn INC. | $34.49 | 2023-2025 | Brixadi |
| Bayer Healthcare Pharmaceuticals INC. | $32.40 | 2024-2025 | |
| Abbvie INC. | $30.30 | 2024-2025 | |
| Neurocrine Biosciences, INC. | $21.57 | 2024 | Ingrezza |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $18.62 | 2024 | Xifaxan |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $16.38 | 2024 | Caplyta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Thomas Meek listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.